A peer-reviewed article by researchers at the University of Shanghai for Science and Technology (USST), published in an international biomedical engineering journal, reports that the Hextra Tech™ ...

The investments we're making to advance and expand our pipeline are increasingly translating into positive clinical results ...

While AstraZeneca's gefurulimab offered significant improvements to MG-ADL scores, it was bested by a variety of ...

During the Phase II MoonStone study (NCT06564311), the bifunctional monoclonal antibody (mAb) met its primary endpoint, ...

Omvoh now offers patients a simplified maintenance experience with one monthly injection, replacing the previous two-injection regimen Omvoh single-injection dosing ...

Approved By U.S. FDA As A Single-Injection Maintenance Regimen In Adults With Ulcerative Colitis. Omvoh now offers patients a simplified maintenance experience with one monthly injection, replacing th ...

Johnson & Johnson today announced new 96-week data from the long-term extensions (LTE) of the Phase 3 GRAVITI, GALAXI 2 and GALAXI 3 studies, which show the durability of TREMFYA® (guselkumab) in ...

Halozyme acquires Elektrofi to expand drug delivery with high-concentration biologics. Discover how this boosts growth and ...

Discover why Viking Therapeutics, Inc.'s VK2735 could lead GLP-1 obesity drugs. Click for my updated look at VKTX stock ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON), today announced that Health Canada has granted a Notice of ...

The presentation will detail results from Hengrui’s Phase 3 clinical trial (GEMINI-1) conducted in China of once-weekly subcutaneous injection of HRS9531, a novel dual GLP-1/GIP receptor agonist, in ...

Viehbacher, “Biogen”) announced today that LEQEMBI ® IQLIK™, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer’s disease (AD) has been selected by ...